Fenofibrate in light of the latest guidelines for the management of dyslipidaemia – why is non-HDL cholesterol so important?

Marcin Barylski

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

1/2018
vol. 4

Send email

Copy url:

abstract:

Review paper

Fenofibrate in light of the latest guidelines for the management of dyslipidaemia – why is non-HDL cholesterol so important?

Marcin Barylski

Online publish date: 2018/03/12

View full text Get citation

Combined lipid disorders, including increased plasma triglycerides levels, low HDL-C, and small, dense LDL particles, comprise atherogenic dyslipidaemia. Observational and clinical studies have shown that these lipid abnormalities are strongly associated with increased risk of macro- and microvascular events even in patients with LDL-C level at goal after statin therapy. Combination pharmacotherapy may significantly improve lipid profile and have a significant impact on cardiovascular risk reduction, which is reflected in the non-HDL cholesterol concentration, the secondary target of treatment in the latest guidelines.

keywords:

Fenofibrate in light of the latest guidelines for the management of dyslipidaemia – why is non-HDL cholesterol so important?

Marcin Barylski

atherogenic dyslipidaemia, non-HDL cholesterol, fenofibrate